Aurinia Pharmaceuticals Inc.

NasdaqGM:AUPH Stock Report

Market Cap: US$1.7b

Aurinia Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGM:AUPH Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
12 Aug 25SellUS$5,435,971ILJIN SNT Co., LtdCompany498,538US$11.49
05 Aug 25BuyUS$13,590,000Tang Capital Management, LLCCompany1,300,000US$11.68
01 Aug 25BuyUS$5,691,488Tang Capital Management, LLCCompany562,400US$10.12
01 Aug 25SellUS$210,000Gregory KeenanIndividual20,000US$10.50
23 Jul 25SellUS$944,680Eun Huh SeoungIndividual108,000US$8.91
07 Mar 25SellUS$68,350Gregory KeenanIndividual8,305US$8.23
04 Mar 25BuyUS$12,713,126Tang Capital Management, LLCCompany1,600,000US$8.09
04 Mar 25BuyUS$12,713,126Tang Capital Management, LLCCompany1,600,000US$8.09
04 Mar 25SellUS$994,425Matthew DonleyIndividual124,893US$8.00
04 Mar 25SellUS$975,223Stephen RobertsonIndividual122,479US$8.00
04 Mar 25SellUS$939,612Joseph MillerIndividual118,013US$8.00
04 Mar 25SellUS$2,871,124Peter GreenleafIndividual360,540US$8.00
03 Mar 25SellUS$97,912Gregory KeenanIndividual12,239US$8.00
09 Dec 24BuyUS$10,822,000Tang Capital Management, LLCCompany1,200,000US$9.09
06 Dec 24BuyUS$6,277,000Tang Capital Management, LLCCompany700,000US$9.01

Insider Trading Volume

Insider Buying: AUPH insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of AUPH?
Owner TypeNumber of SharesOwnership Percentage
Public Companies1,123,6080.854%
Individual Insiders2,445,2071.86%
General Public62,160,21847.2%
Institutions65,900,51350.1%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 38.99% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
8.61%
Tang Capital Management, LLC
11,329,500US$145.6m13%5.95%
5.84%
BlackRock, Inc.
7,693,156US$98.9m-12.2%no data
4.11%
ILJIN SNT Co., Ltd
5,411,533US$69.5m-15.4%no data
3.02%
New Enterprise Associates, Inc.
3,969,834US$51.0m0%2.64%
2.12%
State Street Global Advisors, Inc.
2,795,090US$35.9m-1.97%no data
1.73%
Morgan Stanley, Investment Banking and Brokerage Investments
2,273,344US$29.2m1.03%no data
1.31%
The Vanguard Group, Inc.
1,720,878US$22.1m-12.7%no data
1.24%
Armistice Capital LLC
1,629,600US$20.9m-67.4%0.61%
1.2%
Geode Capital Management, LLC
1,577,060US$20.3m-9.07%no data
0.94%
Qube Research & Technologies Ltd
1,242,512US$16.0m45.1%0.02%
0.88%
Renaissance Technologies LLC
1,157,800US$14.9m23.4%0.02%
0.85%
Lotte Chemical Corporation
1,123,608US$14.4m0%no data
0.82%
Arrowstreet Capital, Limited Partnership
1,076,118US$13.8m-34.4%0.01%
0.71%
Jupiter Fund Management Plc
933,862US$12.0m24.1%0.03%
0.7%
Northern Trust Global Investments
921,271US$11.8m-10.3%no data
0.61%
Lazard Asset Management LLC
798,758US$10.3m-35.8%0.01%
0.58%
UBS Asset Management AG
769,207US$9.9m84.8%no data
0.57%
Jacobs Levy Equity Management Inc
748,113US$9.6m136%0.04%
0.51%
Peter Greenleaf
667,869US$8.6m0%no data
0.5%
Readystate Asset Management LP
657,835US$8.5m0%0.68%
0.49%
Connor, Clark & Lunn Investment Management Ltd.
650,191US$8.4m-12.9%0.03%
0.43%
Union Asset Management Holding AG
565,956US$7.3m98.5%no data
0.42%
Rice Hall James & Associates, LLC
550,501US$7.1m144%0.35%
0.42%
Schroder Investment Management Limited
547,802US$7.0m74%no data
0.39%
Charles Schwab Investment Management, Inc.
511,731US$6.6m-1.86%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/09/26 12:57
End of Day Share Price 2025/09/26 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Aurinia Pharmaceuticals Inc. is covered by 23 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David MartinBloom Burton & Co.
Dae Gon HaBTIG
Neil MaruokaCanaccord Genuity